Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro (tirzepatide) is not suitable for everyone. Adults under 18, people who are pregnant, breastfeeding or trying to conceive, and those with certain medical histories (including a personal or family history of medullary thyroid carcinoma or a condition called MEN2) cannot take it. A prescriber must assess the full picture before treatment can begin, because BMI alone is never the deciding factor. If you've been searching this question late at night, unsure whether your health history rules you out, that's an understandable place to be — and the answer is more nuanced than a simple yes or no. Mounjaro is a prescription-only medicine, which means a GPhC-registered prescriber reviews your complete health profile before anything is dispensed. The NHS medicines page for tirzepatide sets out the main contraindications clearly, and this page walks through each one in plain terms.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Perhaps your GP mentioned something about your thyroid years ago, or you have a family member with a rare endocrine condition, and now you're wondering whether that closes the door on tirzepatide. The clearest contraindications are a personal or family history of medullary thyroid carcinoma (a specific type of thyroid cancer, distinct from the more common forms), and Multiple Endocrine Neoplasia type 2, a genetic syndrome that raises MTC risk. If either applies, Mounjaro is not appropriate, full stop. That isn't a bureaucratic caution, it reflects how the medicine acts on thyroid tissue in animal studies, and the clinical consensus is that the risk cannot be quantified in humans with these histories.
Beyond those two, a previous episode of pancreatitis sits in a slightly different category. The MHRA's Drug Safety Update communications have highlighted acute pancreatitis as a known, if infrequent, risk with GLP-1 class medicines. Someone with a history of pancreatitis isn't automatically excluded, but the prescriber will weigh the individual circumstances carefully, and in many cases will decline to prescribe. If you've had gallbladder disease, that conversation matters too, because this class of medicine can affect gallbladder function.
Serious allergic reactions to tirzepatide or any component of the pen are also an absolute contraindication. If you've had a reaction to a previous GLP-1 medicine, tell the prescriber, it may or may not transfer to tirzepatide, but it is essential clinical information. The full Mounjaro overview has more background on how the medicine works and what it contains.
Mounjaro is not licensed for under-18s. That's a regulatory boundary, not a clinical judgment call about a particular teenager's weight, there simply isn't sufficient trial data in that age group for a licence to have been granted, and no legitimate UK prescriber will issue it for a minor.
For women of childbearing age, the picture is more involved. Mounjaro is not recommended during pregnancy, animal studies raised concerns about fetal development, and that evidence base is enough for regulators to say no. If you are pregnant when you start a consultation, treatment will not be approved. If you become pregnant while on treatment, you should stop and contact your prescriber and GP promptly.
Breastfeeding is also in the not-recommended category, because it's not yet known whether tirzepatide passes into breast milk or what effect that might have on an infant. Trying to conceive sits alongside it: the MHRA advises using effective contraception while on treatment and during a wash-out period afterwards. There's an added practical point for women taking a combined oral contraceptive pill, because Mounjaro slows gastric emptying, pill absorption may be reduced during the first four weeks of treatment and for four weeks after each dose increase. NHS guidance recommends adding a non-oral method (condoms, for example) during those windows. The eligibility guide for Mounjaro covers these points alongside the BMI and comorbidity criteria for those who can proceed.
Some conditions sit between a hard contraindication and a straightforward green light. They don't rule Mounjaro out, but they mean the prescriber needs the full story before deciding. Severe kidney impairment is one, tirzepatide hasn't been studied extensively in that population, and severe fluid loss from vomiting or diarrhoea during treatment can put additional strain on already compromised kidneys. Liver disease follows similar logic. Diabetic retinopathy is another area where vigilance matters: rapid improvements in blood-sugar control have been associated with short-term worsening of retinopathy in some people, so anyone with this condition needs the prescriber to know about it upfront.
Medicines that interact with Mounjaro also shape eligibility decisions. Slow gastric emptying can change how quickly other oral medicines are absorbed, not always to a clinically significant degree, but for certain drugs with narrow therapeutic windows, it is worth discussing. If you take warfarin, thyroid hormone replacement, or medicines for epilepsy, list them in your consultation.
Cost is occasionally a factor people raise at this stage too, if you're unsure whether treatment is affordable before you've established whether it's even appropriate for you, the context around UK Mounjaro pricing may be useful background reading. But the medical picture comes first. A prescriber reviewing your answers at nume's consultation 's consultation, will go through all of this and tell you clearly where you stand.
Being told you can't take Mounjaro isn't necessarily permanent. Pregnancy ends. Some medical situations change. If you want a detailed breakdown of the health and lifestyle factors that determine suitability, the guidance on who can take Mounjaro sets out the clinical picture clearly. And for people whose BMI or health profile places them outside the licensed criteria, there may be other approaches worth exploring, a wider look at weight-loss treatment options can help you see what else might fit your circumstances.
A genuine clinical assessment by a named prescriber, not a tick-box form, is how any reputable service should handle these questions. At nume, every consultation is read by a GPhC-registered Independent Prescriber the same day. If treatment isn't appropriate, they will say so, and explain why. That's the only honest way to run a service for a prescription-only medicine. You can also browse the frequently asked questions for answers to other common queries, or review who we are if you'd like to understand more about how the service is run before you start. If you want to confirm the specific requirements before you begin, the page on who can get Mounjaro and the related guide on who can use Mounjaro both walk through the criteria in plain terms. Check your eligibility by starting a free consultation whenever you're ready.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.